Lung Cancer CRO Services

PHARMExcel provides specialist Lung Cancer CRO Services for sponsors conducting clinical trials across non-small cell lung cancer, small cell lung cancer and biomarker-defined thoracic oncology settings. We work with biotechs, medtech companies, charities and NHS or academic sponsors, as well as US and EU-based organisations, to help deliver studies that are scientifically robust, operationally realistic and aligned with the needs of patients, investigators and specialist oncology sites.

Lung cancer research is one of the most complex areas of oncology. Disease stage, histology, biomarker status, treatment line and the pace of clinical deterioration can all influence how a study needs to be designed and delivered. PHARMExcel supports sponsors with the governance, regulatory strategy and clinical operations needed to run these studies in a way that is feasible, compliant and patient centred.

Understanding NSCLC, SCLC and biomarker-led lung cancer trials

Lung cancer clinical trials are used to evaluate treatments across a broad range of settings, including early stage disease, locally advanced disease and metastatic cancer. These studies may involve non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and molecularly defined populations selected by biomarkers such as EGFR, ALK, ROS1, KRAS or PD-L1. Each of these settings brings different treatment pathways, endpoint priorities and operational pressures.

Because lung cancer care is increasingly shaped by molecular testing, imaging, systemic treatment sequencing and multidisciplinary decision-making, protocols need to reflect more than tumour type alone. Studies may rely on radiographic response, progression-free survival, overall survival, biomarker-driven eligibility, symptom burden and patient-reported outcomes. Capturing those data consistently requires careful protocol planning, specialist site oversight and an operational model that fits real clinical practice.

Managing complexity across early, advanced and heavily pretreated settings

Lung cancer studies can be particularly demanding because many patients have significant symptom burden, multiple comorbidities and rapidly changing clinical status. In early-stage settings, trials may need to align with surgery, radiotherapy or neoadjuvant and adjuvant treatment pathways. In advanced disease, the challenge may be prior treatment history, resistance mechanisms, narrow biomarker-defined populations or the burden of repeated assessments and imaging.

PHARMExcel helps sponsors shape and deliver protocols that reflect these realities. Our role is to ensure that study plans are feasible in the setting in which they will be delivered, with appropriate consideration of disease stage, molecular stratification, imaging requirements, endpoint strategy and participant burden. Whether a study is focused on targeted therapies, immunotherapies, antibody-drug conjugates, radiopharmaceuticals or observational lung cancer research, we help ensure that the trial design is practical as well as scientifically robust.

Delivering lung cancer studies through specialist thoracic oncology centres

PHARMExcel provides governance and oversight across lung cancer trial delivery, including study start-up, site selection, monitoring, project management and close out. We work with sponsors to identify the most appropriate thoracic oncology centres, respiratory oncology services and specialist investigators for each protocol, based on patient population, assessment requirements and study complexity.

Our teams focus on ensuring that trial processes are practical and clearly understood by sites, particularly where studies involve biomarker screening, imaging-heavy follow-up, repeated safety assessments, complex treatment sequencing or longer-term efficacy endpoints. We do not directly recruit patients, but we help sponsors establish realistic, site-led enrolment pathways and maintain operational control throughout the study lifecycle.

Regulatory oversight, imaging endpoints and data quality

PHARMExcel supports lung cancer studies with the regulatory and governance input needed to keep trials compliant, well documented and operationally sound. This includes support with ethics committee and regulatory submissions, safety reporting, monitoring oversight, medical writing and data management processes that reflect the needs of the protocol and the patient population.

Lung cancer trials often depend on consistent endpoint capture across multiple visits and investigators, particularly where radiographic response, progression events, biomarker-defined eligibility, symptom reporting or treatment-related toxicity are central to the study. Our role is to help sponsors maintain data quality, protocol fidelity and audit readiness through clear oversight and proportionate clinical trial management.

Supporting patients through intensive treatment and follow-up pathways

Patient pathways in lung cancer research can be demanding. Trial participation may sit alongside breathlessness, fatigue, pain, systemic treatment, imaging, hospital visits and wider concerns about prognosis and quality of life. This means protocols need to be designed with realistic scheduling, clear communication and careful attention to burden on both participants and site teams.

PHARMExcel helps sponsors and sites ensure that study procedures are deliverable within real thoracic oncology pathways. This is particularly important in lung cancer studies, where the pace of disease progression, the intensity of follow-up and the burden of treatment-related side effects can all influence retention, protocol adherence and the overall acceptability of the study.

Why sponsors choose PHARMExcel for lung cancer CRO support

Sponsors choose PHARMExcel because we combine therapeutic understanding, agile clinical operations and a quality-driven approach to trial governance. As a smaller specialist CRO based in the UK, we offer direct access to senior staff, continuity of team and the flexibility and personal service that larger organisations often struggle to match. This is particularly valuable in lung cancer studies, where biomarker pathways, treatment sequencing and protocol complexity can shift quickly.

Our UK base gives sponsors practical insight into NHS and academic research environments, while our way of working is not limited to UK-based clients. We support sponsors across the UK, Europe and the US who need a responsive CRO partner with strong oversight, clear communication and a realistic understanding of how complex thoracic oncology studies are delivered in practice.

Our aim is to reduce operational burden, support regulatory readiness and help sponsors deliver high-quality lung cancer clinical trials that are feasible in practice as well as robust on paper. For organisations looking for a collaborative and responsive CRO partner in lung cancer research, PHARMExcel provides practical expertise grounded in real-world clinical trial delivery.

Lung Cancer CRO FAQs

What types of lung cancer studies can PHARMExcel support?

PHARMExcel can support clinical trials across non-small cell lung cancer, small cell lung cancer and biomarker-defined thoracic oncology settings. This includes early stage, locally advanced and metastatic studies, as well as trials involving targeted therapies, immunotherapies, radiopharmaceuticals and observational or registry-based programmes.

Which phases of lung cancer trials can PHARMExcel manage?

PHARMExcel supports Phase I-IV clinical trials in oncology research. Our role begins at the clinical trial stage, providing governance, regulatory support and operational oversight once a sponsor is ready to move into human studies.

How does PHARMExcel approach enrolment in lung cancer studies?

PHARMExcel does not directly recruit patients. Instead, we provide governance and oversight of site-led enrolment by helping sponsors identify suitable thoracic oncology centres, assess realistic patient pathways and work with investigators who understand the local population, biomarker profile and treatment setting.

What makes lung cancer clinical trials operationally complex?

Lung cancer studies often involve biomarker-defined populations, intensive imaging, rapidly evolving standards of care, significant symptom burden and complex treatment sequencing. Trials may also need to account for disease progression, comorbidities and long-term follow-up, all of which can affect feasibility and data interpretation.

How does PHARMExcel ensure regulatory compliance in lung cancer trials?

We support sponsors with ethics committee and regulatory submissions, safety reporting, monitoring oversight, data management and trial documentation in line with Good Clinical Practice and relevant UK regulatory expectations. Our quality-driven approach helps ensure studies remain compliant, well governed and audit ready.

Why choose PHARMExcel as a lung cancer CRO?

Sponsors choose PHARMExcel for our responsive, quality-led approach to clinical trial delivery. As a smaller, specialist CRO based in the UK, we provide direct access to senior staff, continuity of team and practical oversight across the trial lifecycle, helping lung cancer studies remain feasible, compliant and patient centred.